Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.77)
# 758
Out of 4,650 analysts
149
Total ratings
56.67%
Success rate
40.12%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $16.66 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $20.18 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $928.61 | -8.47% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.46 | +1,132.88% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $4.92 | +1,119.51% | 3 | Sep 7, 2023 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Overweight | $16 | $59.68 | -73.19% | 5 | Aug 22, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $3.37 | +167.06% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $3.39 | +902.95% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $185.01 | +76.75% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $7.92 | +278.79% | 4 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $71 | $1.93 | +3,578.76% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $476.37 | -41.01% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.63 | +390.80% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $2.87 | +3,314.63% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $317.17 | -6.99% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $88.76 | -3.11% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $24.35 | +97.13% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $24.79 | +21.02% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $46.08 | +56.25% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.84 | +171.74% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $65.69 | +52.23% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $28 → $24 | $0.37 | +6,325.70% | 3 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $129.44 | +55.28% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $40.48 | +109.98% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $7.24 | +341.99% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $130.26 | +66.59% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $30.49 | +57.43% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $9.11 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $286.91 | -46.32% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $70.13 | +65.41% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $2.83 | +3,645.58% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $16.34 | +71.36% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $162.20 | -49.45% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $349.71 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.00 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.66
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.18
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $928.61
Upside: -8.47%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.46
Upside: +1,132.88%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $4.92
Upside: +1,119.51%
Longboard Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $59.68
Upside: -73.19%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $3.37
Upside: +167.06%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $3.39
Upside: +902.95%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $185.01
Upside: +76.75%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $7.92
Upside: +278.79%
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $1.93
Upside: +3,578.76%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $476.37
Upside: -41.01%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.63
Upside: +390.80%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $2.87
Upside: +3,314.63%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $317.17
Upside: -6.99%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $88.76
Upside: -3.11%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $24.35
Upside: +97.13%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $24.79
Upside: +21.02%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $46.08
Upside: +56.25%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.84
Upside: +171.74%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $65.69
Upside: +52.23%
May 5, 2020
Reiterates: Overweight
Price Target: $28 → $24
Current: $0.37
Upside: +6,325.70%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $129.44
Upside: +55.28%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $40.48
Upside: +109.98%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $7.24
Upside: +341.99%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $130.26
Upside: +66.59%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $30.49
Upside: +57.43%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $9.11
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $286.91
Upside: -46.32%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $70.13
Upside: +65.41%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $2.83
Upside: +3,645.58%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $16.34
Upside: +71.36%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $162.20
Upside: -49.45%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $349.71
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.00
Upside: -